541400 — Zim Laboratories Balance Sheet
0.000.00%
- IN₹3.34bn
- IN₹4.49bn
- IN₹3.79bn
- 75
- 34
- 23
- 39
Annual balance sheet for Zim Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 108 | 116 | 64.2 | 102 | 23.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 728 | 898 | 989 | 1,035 | 1,069 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,918 | 2,121 | 1,909 | 2,276 | 2,313 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,052 | 1,069 | 1,216 | 1,804 | 2,024 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,248 | 3,416 | 3,416 | 4,468 | 4,720 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,420 | 1,459 | 1,108 | 1,594 | 1,664 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,640 | 1,659 | 1,412 | 2,081 | 2,198 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 1,608 | 1,757 | 2,003 | 2,387 | 2,522 |
| Total Liabilities & Shareholders' Equity | 3,248 | 3,416 | 3,416 | 4,468 | 4,720 |
| Total Common Shares Outstanding |